
Opinion|Videos|March 10, 2025
Molecular Monitoring Advances in PV Disease Assessment and Management
Author(s)Prithviraj Bose, MD
A panelist discusses how advances in JAK2 V617F and other molecular monitoring have enhanced their ability to assess polycythemia vera (PV) disease progression and guide initial treatment decisions by providing quantifiable markers for tracking mutation burden, treatment response, and risk stratification that complement traditional clinical parameters.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please explain how advances in JAK2 V617Fand other molecular monitoring have enhanced your ability to assess disease progression and guide initial treatment decisions for your patients with PV.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5







































